ARTICLE | Clinical News
KS Biomedix to begin Phase IIb RA trial
May 11, 2001 7:00 AM UTC
KS Biomedix (LSE:KSB) will begin a European Phase IIb dose-escalation trial of its KSB302 small molecule in 300 patients with rheumatoid arthritis (RA). KSB expects to complete the trial, which will e...